Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention

Trial Profile

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Biohaven Pharmaceutical
  • Most Recent Events

    • 21 Nov 2018 Planned primary completion date changed from 15 Feb 2020 to 30 Sep 2019.
    • 15 Nov 2018 According to a Biohaven Pharmaceutical media release, first patient has been enrolled in this study. Top-line result from this study is expected in 2019.
    • 15 Nov 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top